← Back to Search

Dopamine Agonist

High-Dose Requip for Parkinson's Disease

Phase 3
Waitlist Available
Led By Pinky Agarwal, MD
Research Sponsored by Agarwal, Pinky, M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must be on a maximum dose of dopamine agonist drug (pergolide 4mg/day, pramipexole 4.5 mg/day or ropinirole 24mg/day)
Age greater than or equal to 25 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing if Requip, a drug used to treat Parkinson's, is more effective at a higher dose than what is currently FDA approved.

Who is the study for?
This trial is for Parkinson's patients over 25 years old who are already on the highest approved dose of dopamine agonist drugs and have motor fluctuations or dyskinesias. They must not be pregnant, use reliable contraception if applicable, and have been on stable medication doses for 4 weeks.Check my eligibility
What is being tested?
The study tests whether a higher than FDA-approved dose of Requip can benefit Parkinson's patients with 'on' and 'off' states and involuntary movements. This high-dose usage of Requip is investigational and not yet approved by the FDA.See study design
What are the potential side effects?
Potential side effects may include hallucinations, swelling (edema), depression changes, as well as other risks typically associated with dopamine agonists like nausea, dizziness, sleepiness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am taking the highest dose of my Parkinson's medication.
Select...
I am 25 years old or older.
Select...
I am not pregnant and agree to use birth control during the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Agarwal, Pinky, M.D.Lead Sponsor
Colorado NeurologyOTHER
GlaxoSmithKlineIndustry Sponsor
4,746 Previous Clinical Trials
8,067,017 Total Patients Enrolled

Media Library

Ropinirole (Requip) (Dopamine Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT00260793 — Phase 3
Parkinson's Disease Research Study Groups:
Parkinson's Disease Clinical Trial 2023: Ropinirole (Requip) Highlights & Side Effects. Trial Name: NCT00260793 — Phase 3
Ropinirole (Requip) (Dopamine Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00260793 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who meets the screening requirements for this particular medical experiment?

"20 individuals, aged 25 or older and currently suffering from parkinson disease, are being enrolled in this clinical trial. However, it is essential that these patients also meet the following age criterion: greater than or equal to 25 years old."

Answered by AI

We are interested in patients who fall within the 20-year age bracket - does this study apply to them?

"To be applicable for this particular study, patients must between the ages of 25 and 50. Out of 514 total clinical trials, 28 are specifically geared towards minors while the remaining 486 are for senior citizens."

Answered by AI

Has this medication been cleared by the FDA?

"This clinical trial is in Phase 3, which suggests that while there is evidence of the treatment's efficacy, multiple rounds of data support its safety. Consequently, our team rates this treatment as a 3 on our scale."

Answered by AI

Are new patients currently being enrolled in this clinical trial?

"According to the information on clinicaltrials.gov, this trial is not currently looking for patients. This study was first posted on November 1st 2005 and last updated February 2nd 2006. Although this particular trial isn't searching for candidates, there are 517 other ongoing studies that are actively recruiting patients right now."

Answered by AI
~1 spots leftby Mar 2025